NVAX earnings 11/09 4pm, target $175 by 11/10

17 oct. 2020

Let's start with, I have a love / hate relationship with NVAX. lol. It all began when I bought shares on 5/28/19, 5/30/19, 7/3/19 & 7/16/19 for 5.97, 5.71, 5.41 & 4.64 respectively. Nobody could have predicted what 2020 had in store for all of us. Like the Grateful Dead album, "What a long strange trip it's been". So it goes without saying, I just can't wrap my head around buying anymore shares of NVAX in the the double digits, let alone triple digits, the past 6 months. With that said, there's way more people out there that don't have my avoidance in investing in NVAX at these levels. As far as their NVX-CoV2373 covid-19 vaccine (credit: novavax.com), I think it's the most serious candidate out there. If the data of their Phase 2 clinical trials that started in August, are revealed before or during Q3 earnings and it's a positive result, my target is $175. The technicals show a consolidation with price spreads tightening, with higher lows the past month. So all in all, I'm bullish heading into November. Good luck and happy trading friends...

21 oct. 2020

Note

Good movement for a strangle. Looks like a lot of profit taking this week, selling pressure tanking the stock...

28 oct. 2020

Note

Checkout my price and volume indicators:

<deleted>


<deleted>

10 nov. 2020

Note

Update: I am definitely bearish on NVAX now. Novavax (NVAX) reported a 3rd Quarter September 2020 loss of $3.21 per share on revenue of $157.0 million. The consensus earnings estimate was $2.36 per share on revenue of $234.2 million.